» Articles » PMID: 18440592

Gastric Cancer with High-level Microsatellite Instability: Target Gene Mutations, Clinicopathologic Features, and Long-term Survival

Overview
Journal Hum Pathol
Specialty Pathology
Date 2008 Apr 29
PMID 18440592
Citations 56
Authors
Affiliations
Soon will be listed here.
Abstract

Gastric cancer is one of the leading causes of cancer death worldwide, and although the incidence has decreased in Western countries, specific high-risk areas are present in Italy. Gastric cancer with high-level microsatellite instability (MSI-H) represents a well-defined subset of carcinomas showing distinctive clinicopathologic features. We examined clinicopathologic associations and long-term survival in a series of 159 gastric cancer cases from a high-risk population in Tuscany (central Italy). MSI-H was associated with antral location of the tumor (P = .001), intestinal type according to Lauren classification (P = .002), expanding type according to Ming classification (P = .0001), and mucinous histologic type according to the Japanese Research Society for Gastric Cancer classification (P = .002). In addition, MSI-H was strongly associated with a higher survival at 15 years (P = .01) and with loss of hMLH1 expression, evaluated by immunohistochemistry (P = .001). Multivariate analyses showed a significant association between the absence of hMLH1 reactivity and the expanding tumor type (P = .002). We also investigated the MSI-H-related genetic changes by analyzing coding repeats within target genes involved in pathways that control cell growth (TGFbetaRII, IGFIIR, RIZ, TCF4, DP2), apoptosis (BAX, BCL10, FAS, CASPASE5, APAF1), and DNA repair genes (hMSH6, hMSH3, MED1, RAD50, BLM, ATR, BRCA2, MRE11). Gastric cancer cases with MSI-H were found to accumulate heterozygous mutations affecting multiple molecular pathways and multiple genes within each pathway. Intriguingly, in this subset, TGFbetaRII mutations appeared to be inversely related to BLM mutations (P = .006), whereas RAD50 mutation carriers showed significantly reduced survival (P = .03).

Citing Articles

Current Landscape of Molecular Biomarkers in Gastroesophageal Tumors and Potential Strategies for Co-Expression Patterns.

Korpan M, Puhr H, Berger J, Friedrich A, Prager G, Preusser M Cancers (Basel). 2025; 17(3).

PMID: 39941712 PMC: 11816248. DOI: 10.3390/cancers17030340.


Access to radiotherapy in improving gastric cancer care quality and equality.

Wang M, Huang K, Fan X, Wang J, Jin Y, Zheng Z Commun Med (Lond). 2024; 4(1):225.

PMID: 39488624 PMC: 11531536. DOI: 10.1038/s43856-024-00655-z.


Potent therapeutic strategy in gastric cancer with microsatellite instability-high and/or deficient mismatch repair.

Ooki A, Osumi H, Yoshino K, Yamaguchi K Gastric Cancer. 2024; 27(5):907-931.

PMID: 38922524 PMC: 11335850. DOI: 10.1007/s10120-024-01523-4.


Prime Editing and DNA Repair System: Balancing Efficiency with Safety.

Daliri K, Hescheler J, Pfannkuche K Cells. 2024; 13(10.

PMID: 38786078 PMC: 11120019. DOI: 10.3390/cells13100858.


A Clinical Viewpoint on the Use of Targeted Therapy in Advanced Gastric Cancer.

Skorzewska M, Geca K, Polkowski W Cancers (Basel). 2023; 15(22).

PMID: 38001751 PMC: 10670421. DOI: 10.3390/cancers15225490.